• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2011 Fiscal Year Final Research Report

Mechanism of multidrug resistance in mesothelioma cells, and the treatment strategy targeting CD44

Research Project

  • PDF
Project/Area Number 21591003
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Respiratory organ internal medicine
Research InstitutionJuntendo University

Principal Investigator

TAKAHASHI Kazuhisa  順天堂大学, 医学部, 教授 (80245711)

Co-Investigator(Kenkyū-buntansha) SUZUKI Tsutomu  順天堂大学, 医学部, 准教授 (40206503)
Project Period (FY) 2009 – 2011
Keywords悪性中皮腫 / 抗癌剤多剤耐性 / CD44 / オステオポンチン / ヒアルロン酸
Research Abstract

Malignant pleural mesothelioma(MPM) is resistant to chemotherapy and thus shows a dismal prognosis. Osteopontin(OPN) and hyaluronate(HA), both of which are CD44 ligands, are highly detected in the pleural effusion and tissues of MPM, and suggested to be involved in the pathogenesis of MPM. However, the precise role of CD44, OPN, and HA, especially in the multidrug resistance of MPM, remains to be elucidated. We therefore established stable transfectants(ACC-MESO-1/OPN) of human mesothelioma cell line, which constitutively express OPN, to determine its role in the chemoresistance observed in MPM. The introduction of the OPN gene provides MPM cells with upregulated multidrug resistance through the mechanism of enhanced HA binding. The expression of CD44 variant isoforms, which inhibit HA binding, significantly decreased in ACC. MESO. 1/OPN cells in comparison to control transfectants. Interestingly, the inhibition of the HA-CD44 interaction abrogated multidrug resistance in the ACC. MESO. 1/OPN, thus suggesting the involvement of the surviving signal emanating from the HA-CD44 interaction. An enhanced level of the p-Akt in ACC. MESO. 1/OPN cells was observed, and was diminished by CD44 siRNA. Inhibition of the Akt phosphorylation increased in number of the cells underwent apoptosis induced by chemotherapeutic drugs, such as NVB, VP-16 and GEM. Collectively, these results indicate that OPN is strongly involved in multidrug resistance by enhancing the CD44 binding to HA. Inhibition of interaction between CD44, OPN, and HA, may be one of the promising treatment strategy for patients with MPM.

  • Research Products

    (5 results)

All 2010 2009 2007 2006

All Journal Article (2 results) (of which Peer Reviewed: 2 results) Presentation (3 results)

  • [Journal Article] Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells2010

    • Author(s)
      Tajima K, Ohashi R, Takahashi K, et al.
    • Journal Title

      Oncogene

      Volume: 29(13) Pages: 1941-51

    • Peer Reviewed
  • [Journal Article] Osteopontin modulates malignant pleural mesothelioma cell functions in vitro2009

    • Author(s)
      Ohashi R, Tajima K, Takahashi K, et al.
    • Journal Title

      Anticancer Res

      Volume: 29(6) Pages: 2205-14

    • Peer Reviewed
  • [Presentation] Osteopontin mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells2009

    • Author(s)
      Tajima K, Ohashi R, Takahashi K, et al.
    • Organizer
      104^<th> American Thoracic Society(ATS)
    • Place of Presentation
      San Diego, USA
    • Year and Date
      2009-05-19
  • [Presentation] Role of osteopontin in malignant pleural mesothelioma cell line2007

    • Author(s)
      Ohashi R, Takahashi K, et al.
    • Organizer
      102^<th> American Thoracic Society(ATS)
    • Place of Presentation
      San Francisco, USA
    • Year and Date
      2007-05-23
  • [Presentation] Expression of osteopontin and CD44 in malignant pleural mesothelioma cell lines(poster session)2006

    • Author(s)
      Ohashi R, Takahashi F, Takahashi K, et al.
    • Organizer
      11^<th> Congress of the Asian Pacific Society of Respirology(APSR)
    • Place of Presentation
      Japan
    • Year and Date
      2006-11-21

URL: 

Published: 2013-07-31  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi